thalidomide has been researched along with Multiple System Atrophy Syndrome in 1 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Multiple system atrophy (MSA) is a fatal neurodegenerative disorder characterized by the pathological accumulation of alpha-synuclein (α-syn) in oligodendrocytes." | 7.85 | Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy. ( Adame, A; Desplats, P; Fields, JA; Mante, M; Masliah, E; Rockenstein, E; Spencer, B; Trinh, I; Valera, E, 2017) |
| "Multiple system atrophy (MSA) is a fatal neurodegenerative disorder characterized by the pathological accumulation of alpha-synuclein (α-syn) in oligodendrocytes." | 3.85 | Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy. ( Adame, A; Desplats, P; Fields, JA; Mante, M; Masliah, E; Rockenstein, E; Spencer, B; Trinh, I; Valera, E, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Valera, E | 1 |
| Spencer, B | 1 |
| Fields, JA | 1 |
| Trinh, I | 1 |
| Adame, A | 1 |
| Mante, M | 1 |
| Rockenstein, E | 1 |
| Desplats, P | 1 |
| Masliah, E | 1 |
1 other study available for thalidomide and Multiple System Atrophy Syndrome
| Article | Year |
|---|---|
Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy.
Topics: alpha-Synuclein; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Gliosis; Humans; Immunot | 2017 |